ABP 215 Displays Clinical Similarity to Bevacizumab for Patients With Non-squamous NSCLC

Share this content:
Biosimilar candidate ABP 215 may be clinically interchangeable with bevacizumab for treatment of non-squamous non-small cell lung cancer.
Biosimilar candidate ABP 215 may be clinically interchangeable with bevacizumab for treatment of non-squamous non-small cell lung cancer.

Biosimilar candidate ABP 215, an anti-vascular endothelial growth factor A (anti-VEGF) antibody, may be clinically interchangeable with bevacizumab for treatment of non-squamous non-small cell lung cancer (NSCLC), according to a study presented at the 2016 American Society of Clinical Oncology (ASCO) meeting.1

Researchers enrolled 642 patients to this randomized, active-controlled phase 3 study, in which 328 patients were assigned to the ABP 215 cohort; 314 were assigned to receive bevacizumab. All enrolled patients were also receiving first-line chemotherapy for non-squamous NSCLC.

The pre-specified objective response rate was met by 128 (39%) patients in the ABP 215 group, compared to 131 (41.7%) patients randomized to receive bevacizumab. A comparable percentage of patients--18.8% and 17.2%--discontinued treatment due to adverse events from ABP 215 and bevacizumab, respectively.

RELATED: Pembrolizumab Appears Effective on Brain Metastases in Melanoma, NSCLC

The authors concluded that ABP 215 demonstrated clinical similarity to bevacizumab for treatment of non-squamous NSCLC. Safety profiles in the drugs were also similar; common adverse events included alopecia, nausea, neutropenia, peripheral neuropathy, and hypertension.

Reference

  1. Thatcher N, Thomas M, Paz-Ares L, Ostoros G, Pan Z, Goldschmidt JH, et al. Randomized, double-blind, phase 3 study evaluating efficacy and safety of ABP 215 compared with bevacizumab in patients with non-squamous NSCLC. J Clin Oncol. 2016; 34 (suppl; abstr 9095).

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs